Mashup Score:39
JAMA NetworkSurvival in Patients With Hematologic Cancers and COVID-19 - 1 week
Mashup Score:39
Twitter Feed: Mike Thompson, MD, PhD, FASCO
Mashup Score:9
New England Journal of Medicine (NEJM)Early Outpatient Treatment for Covid-19 with Convalescent Plasma | NEJM - 1 week
Mashup Score:9
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent...
-
Early Outpatient Treatment for Covid-19 with Convalescent Plasma [Mar 30, 2022] @jhDavidSullivan et al. @NEJM https://t.co/Cqht9Cis3c #NCT04373460 #COVID19CP #COVID19 cc @DrMJoyner @DrJPHenderson @DFarmakiotis @covid19nCCC https://t.co/Cqht9Cis3c - view on twitter
Mashup Score:1
www.medrxiv.org| medRxiv - 1 day
Mashup Score:1
medRxiv – The Preprint Server for Health...
-
Characteristics of Patients with Hematologic Malignancies Without Seroconversion Post-COVID19 Third Vaccine Dosing {preprint} [Apr 16, 2022] Hallmeyer et al. @medrxivpreprint https://t.co/RZhhxFwJbu #COVID19Vaccine #COVID19nCancer #bmtsm #leusm #lymsm #mmsm #mpnsm #IDonc https://t.co/RZhhxFwJbu - view on twitter
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and...
-
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/g3GP7EsUeS - view on twitter
PURPOSE Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of...
-
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients with Breast Cancer Enrolled in a Cooperative Group Clinical Trial (@SWOG S0221) [Dec 19, 2019] Ambrosone @cambros1 et al. @JCO_ASCO https://t.co/ZNBT5fdRRv #scicomm #oncopharm #bcsm - view on twitter
CCC19 is a consortium of 120+ organizations that are working together to collect data about patients with cancer who have been diagnosed with...
-
RT @COVID19nCCC: Map of Participating Institutions (N=126) - COVID-19 and Cancer Consortium (#CCC19) [Apr 20, 2022] https://t.co/xqZPC8wTjd… - view on twitter
More coverage:
#ccc19
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk...
-
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory - view on twitter
COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors...
-
Definition of factors associated with negative antibody response after COVID-19 vaccination in Pts w/ hematological diseases [May 21, 2022] Rotterdam et al. Annals of Hematology https://t.co/lSI3zQWfnn #COVID19Vaccine #COVID19nCancer #IDonc #COVID19 #mmsm #leusm #lymsm #mpnsm https://t.co/lSI3zQWfnn - view on twitter
e19513 Background: Patients (Pts) with hematologic malignancies (HM) are at greater risk of severe morbidity and mortality caused by COVID19 and show a lower...
-
Characteristics of Pts w/ hematologic malignancies w/o seroconversion post-#COVID19 3rd vaccine dosing (3V): Real-world data from large midwestern healthcare system [Jun 2, 2022] Hallmeyer et al. @JimW9200 Abstract e19513 #ASCO22 https://t.co/22Q2IGyoS6 #COVID19Vaccine #IDonc https://t.co/22Q2IGyoS6 - view on twitter
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent...
-
Early Outpatient Treatment for Covid-19 with Convalescent Plasma [Mar 30, 2022] @jhDavidSullivan et al. @NEJM https://t.co/Cqht9Cis3c #NCT04373460 #COVID19CP #COVID19 https://t.co/Cqht9Cis3c - view on twitter
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and...
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/g3GP7EsUeS - view on twitter